Identification of a Natural Soluble Neuropilin-1 That Binds Vascular Endothelial Growth Factor: In Vivo Expression and Antitumor Activity

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2000 Feb 26

PMID 10688880

Citations 116

Authors

M L Gagnon

D R Bielenberg

Z Gechtman

H Q Miao

S Takashima

S Soker

M Klagsbrun

Affiliations

Soon will be listed here.

Abstract

Neuropilin-1 (NRP1) is a 130-kDa transmembrane receptor for semaphorins, mediators of neuronal guidance, and for vascular endothelial growth factor 165 (VEGF(165)), an angiogenesis factor. A 2.2-kb truncated NRP1 cDNA was cloned that encodes a 644-aa soluble NRP1 (sNRP1) isoform containing just the a/CUB and b/coagulation factor homology extracellular domains of NRP1. sNRP1 is secreted by cells as a 90-kDa protein that binds VEGF(165), but not VEGF(121). It inhibits (125)I-VEGF(165) binding to endothelial and tumor cells and VEGF(165)-induced tyrosine phosphorylation of KDR in endothelial cells. The 3' end of sNRP1 cDNA contains a unique, 28-bp intron-derived sequence that is absent in full-length NRP1 cDNA. Using a probe corresponding to this unique sequence, sNRP1 mRNA could be detected by in situ hybridization differentially from full-length NRP1 mRNA, for example, in cells of liver, kidney, skin, and breast. Analysis of blood vessels in situ showed that NRP1, but not sNRP1, was expressed. sNRP1 was functional in vivo. Unlike control tumors, tumors of rat prostate carcinoma cells expressing recombinant sNRP1 were characterized by extensive hemorrhage, damaged vessels, and apoptotic tumor cells. These results demonstrate the existence of a naturally occurring, soluble NRP1 that is expressed differently from intact NRP1 and that appears to be a VEGF(165) antagonist.

Citing Articles

Neuropilin1-dependent paracrine signaling of cancer cells mediated by miRNA exosomal cargo.

Palazzo C, Mastrantonio R, Gioelli N, Testa E, Recco F, Lucchetti D Cell Commun Signal. 2025; 23(1):54.

PMID: 39875894 PMC: 11776261. DOI: 10.1186/s12964-025-02061-x.

Potential Effects of Hyperglycemia on SARS-CoV-2 Entry Mechanisms in Pancreatic Beta Cells.

Michaels T, Essop M, Joseph D Viruses. 2024; 16(8).

PMID: 39205219 PMC: 11358987. DOI: 10.3390/v16081243.

SARS-CoV-2 Rapidly Infects Peripheral Sensory and Autonomic Neurons, Contributing to Central Nervous System Neuroinvasion before Viremia.

Joyce J, Moore G, Goswami P, Harrell T, Taylor T, Hawks S Int J Mol Sci. 2024; 25(15).

PMID: 39125815 PMC: 11311394. DOI: 10.3390/ijms25158245.

Soluble Neuropilin-1 Is Elevated in Sepsis and Correlates with Organ Dysfunction and Long-Term Mortality in Critical Illness.

Hohlstein P, Schumacher E, Abu Jhaisha S, Adams J, Pollmanns M, Schneider C Int J Mol Sci. 2024; 25(10).

PMID: 38791476 PMC: 11121523. DOI: 10.3390/ijms25105438.

Cardiometabolic and immune response to exercise training in patients with metabolic syndrome: retrospective analysis of two randomized clinical trials.

Lechner K, Kia S, von Korn P, Dinges S, Mueller S, Tjonna A Front Cardiovasc Med. 2024; 11:1329633.

PMID: 38638882 PMC: 11025358. DOI: 10.3389/fcvm.2024.1329633.

References

Isaacs J, Isaacs W, Feitz W, Scheres J . Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate. 1986; 9(3):261-81. DOI: 10.1002/pros.2990090306. View

Klagsbrun M, DAmore P . Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 1996; 7(3):259-70. DOI: 10.1016/s1359-6101(96)00027-5. View

Petch L, Harris J, Raymond V, Blasband A, Lee D, Earp H . A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue. Mol Cell Biol. 1990; 10(6):2973-82. PMC: 360661. DOI: 10.1128/mcb.10.6.2973-2982.1990. View

Johnson D, Lu J, Chen H, Werner S, Williams L . The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol. 1991; 11(9):4627-34. PMC: 361347. DOI: 10.1128/mcb.11.9.4627-4634.1991. View

Dvorak H, Sioussat T, Brown L, Berse B, Nagy J, Sotrel A . Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med. 1991; 174(5):1275-8. PMC: 2118980. DOI: 10.1084/jem.174.5.1275. View

Soker S, Vlodavsky I, Neufeld G . The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem. 1992; 267(9):6093-8. View

Plate K, Breier G, Weich H, Risau W . Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992; 359(6398):845-8. DOI: 10.1038/359845a0. View

Radinsky R, Bucana C, Ellis L, Sanchez R, Cleary K, Brigati D . A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res. 1993; 53(5):937-43. View

Bucana C, Radinsky R, Dong Z, Sanchez R, Brigati D, Fidler I . A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdr1 in mouse colon carcinoma cells. J Histochem Cytochem. 1993; 41(4):499-506. DOI: 10.1177/41.4.8095509. View

10.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

11.

Kendall R, Thomas K . Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993; 90(22):10705-9. PMC: 47846. DOI: 10.1073/pnas.90.22.10705. View

12.

Ferrara N . The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18(1):4-25. DOI: 10.1210/edrv.18.1.0287. View

13.

Benjamin L, Keshet E . Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A. 1997; 94(16):8761-6. PMC: 23118. DOI: 10.1073/pnas.94.16.8761. View

14.

He Z, Tessier-Lavigne M . Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell. 1997; 90(4):739-51. DOI: 10.1016/s0092-8674(00)80534-6. View

15.

Kolodkin A, Levengood D, Rowe E, Tai Y, Giger R, Ginty D . Neuropilin is a semaphorin III receptor. Cell. 1997; 90(4):753-62. DOI: 10.1016/s0092-8674(00)80535-8. View

16.

Lin P, Sankar S, Shan S, Dewhirst M, Polverini P, Quinn T . Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 1998; 9(1):49-58. View

17.

Soker S, Takashima S, Miao H, Neufeld G, Klagsbrun M . Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92(6):735-45. DOI: 10.1016/s0092-8674(00)81402-6. View

18.

Goldman C, Kendall R, Cabrera G, Soroceanu L, Heike Y, Gillespie G . Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A. 1998; 95(15):8795-800. PMC: 21156. DOI: 10.1073/pnas.95.15.8795. View

19.

Lee H, Maihle N . Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues. Oncogene. 1998; 16(25):3243-52. DOI: 10.1038/sj.onc.1201866. View

20.

Giger R, Urquhart E, Gillespie S, Levengood D, Ginty D, Kolodkin A . Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron. 1998; 21(5):1079-92. DOI: 10.1016/s0896-6273(00)80625-x. View